Pembrolizumab in Head and Neck Cancer—Promise and Price

This Viewpoint considers the financial impact of expanding the indication of pembrolizumab for treatment of resectable locally advanced head and neck squamous cell carcinoma expressing programmed cell death 1 ligand 1.

Corresponding Author: Lauren E. Miller, MD, MBA, Department of Otolaryngology–Head lauren.miller@osumc.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.